Our first quarter results have set the stage for a strong 2014. We are experiencing an exciting uptake of our new products, including the NextSeq™ 500 and HiSeq X™ Ten, while demand for the overall product portfolio remains robust. We continue to innovate across the entire spectrum of the sequencing workflow to more broadly enable the adoption of genomics." -- Jay Flatley, CEO.
I particularly like the phrase entire spectrum when it comes to genomics.
Illumina's 1Q'14 press release ended with: "For fiscal 2014 the Company has increased projections [...]".
ILMN closed today (02014.04.22) at $141.21. 52-week range: $59.99 - $183.30. ILMN is up 10+% in after hours trading.
No comments:
Post a Comment